The BE OPTIMAL trial, a phase 3 randomized, double-blind, placebo-controlled study, evaluated the efficacy and safety of bimekizumab in biologic-naive adults with active psoriatic arthritis (PsA)....
Cycling Versus Swapping Strategies With IL-17 Inhibitors in Psoriatic Arthritis
The availability of various biologic disease-modifying anti-rheumatic drugs (bDMARDs) with different mechanisms of action enhances treatment options for psoriatic arthritis...
GRAPPA Consensus on Comprehensive Treatment Recommendations for Psoriatic Arthritis
The objective of this study was to develop comprehensive treatment recommendations for the various clinical manifestations of psoriatic arthritis (PsA),...
Understanding Psoriatic Arthritis: IL-17’s Role and Promising Targeted Therapies
Psoriatic arthritis (PsA) is a chronic inflammatory condition that typically follows psoriasis (PsO), with skin involvement often preceding joint issues,...
This observational study evaluated the long-term clinical outcomes of adalimumab (ADA), etanercept (ETN), and infliximab (IFX) in biologic-naive patients with...
Phosphodiesterases (PDEs) are enzymes that degrade the second messengers cAMP and cGMP, influencing processes like cell proliferation, apoptosis, inflammation, and...
